Robert Mashal - 11 Aug 2025 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Aug 2025, 16:30:14 UTC
Prior SEC filing
23 May 2025
Next SEC filing
26 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Stephen Dang, Attorney-in-Fact

Key filing fact

Robert Mashal filed Form 4 for Nuvation Bio Inc. (NUVB) on 13 Aug 2025.

Key facts

  • This page summarizes Robert Mashal's Form 4 filing for Nuvation Bio Inc. (NUVB).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 13 Aug 2025, 16:30.

Change

  • Previous filing in this sequence was filed on 23 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002007102 Primary reporting owner

Mashal Robert

Relationship
Director
Address
C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK
Signature
/s/ Stephen Dang, Attorney-in-Fact
Signature date
13 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVB transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value
$0
Shares
-350,001
Change %
-47%
Price
$0.000000
Shares after
391,178
Date
11 Aug 2025
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
350,001
Exercise price
$1.55
Footnotes
F1, F2
NUVB transaction Derivative

Stock Option (Right to buy)

Gift

Transaction value
$0
Shares
+350,001
Change %
Price
$0.000000
Shares after
350,001
Date
11 Aug 2025
Ownership
By Trust
Underlying class
Class A Common Stock
Underlying amount
350,001
Exercise price
$1.55
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying the option are fully vested.

Footnote F2

The reported transaction involves the reporting person's transfer of option to his irrevocable trust.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .